London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings

blonca9
Nov 20, 2024
1 min read

CEO Berndt Modig describes the science behind creating both immediate release capsuls and extended release tablets. Successfully developing an oral therapy could set Pharvaris apart.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight